About

Lead Biotherapeutics LTD was founded in 2016 in Sofia, Bulgaria as a privately held company, focusing on advanced technologies for bioavailability improvement.
Lead Biotherapeutics LTD is a proof-of-concept company experienced in innovative pharmaceutical development projects to a therapeutic efficacy and drug safety stage.
We Identify modern therapy problems
Today many therapies including the treatment of social diseases like diabetes, Parkinson’s, Alzheimer’s, cancer, chronic inflammation etc., are affected by obstacles originating from the used drug itself and the limitations of pharmaceutical forms:

• Low systemic or local bioavailability of the applied drug (e.g. insolubility, ionization, substrate of p-Glycoprotein efflux pump, extensive pre-systemic metabolism, chemical instability).

• Small therapeutic window.

• Fast elimination.

Our Solution:

Targeting the majority of existing and future drugs into cells can lead to a significant (sometimes dramatic) increase in drug action and safety.

Our R&D milestones

2020
I-CAN™ Technology patent application will be published until Q2.

2019
CellInject™ Technology patent application has been published.

2018
I-CAN™ Technology and composition patent filed.
CellInject™ Technology trademark granted.
I-CAN™ Technology trademark graned.

2017
5 clinical cases with low dosed nasal loratadine plus xylometazoline combination with I-CAN™ Technology have been completed.
17 clinical cases with low dosed nasal mometasone plus xylometazoline combination with I-CAN™ Technology have been completed.
CellInject™ Technology and composition patent filed.

2016
Lead Biotherapeutics company founded.
Upgraded SLN composition into CellInject™ Technology.
Developed a new CellInject™ based technology called I-CAN™ Technology.
First 15 clinical cases with low dosed nasal mometasone spray with I-CAN™ Technology have been completed.

2015
First efficacy data on rabbit dermal induced histamine wheals.

2014
First toxicological data of synthesized SLN on HaCaT cell line (immortalized human keratinocyte cell line).
First safety data of synthesized SLN on rabbit nasal mucosa and rabbit ocular surface integrity.

2013

Starting R&D on SLN.
Early SLN compositions.
Adjusting technology parameters.